Overview

Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy

Status:
Terminated

Trial end date:
2005-04-01

Target enrollment:

Participant gender:

Summary

This study is being done to evaluate the safety, tolerability and satisfactory relief of tegaserod against dyspeptic symptoms in diabetic patients with symptoms of diabetic gastropathy.

Phase:

Phase 2

Details

Lead Sponsor:

Novartis

Treatments:

Tegaserod